 |
 |
|||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
|||||
|
|||||||||||||||||||||
|
|
Release date: October 9, 2006 Program Description New therapies targeting the epidermal growth factor receptor (EGFR) have been used in the treatment of a variety of cancers. Although generally well tolerated, EGFR inhibitors are associated with the development of dermatologic reactions (e.g., papulopustular rash, xerosis, pruritus, periungual inflammation, and alopecia) in most patients. At present, little is known about the etiology of these reactions, and no evidence-based management guidelines have been set forth in the dermatologic literature. Early recognition of and attention to any new skin reaction is important, as is distinguishing between typical rash presentation, secondary infection, and steroid-induced acne. Of interest, data from clinical studies have shown a positive correlation between the development of rash and response and/or survival, thus suggesting that rash may be a surrogate marker of efficacy. The possibility that EGFR inhibitor-related rash is associated with success of treatment offers the potential to titrate the dosing of chemotherapeutic agents on a case-by-case basis. Lack of rash may signal the need for alternative therapy (if available) or an increase in dose (if maximum-tolerated dose is not being used), whereas the presence of rash may allow dose reduction. Target Audience This activity is intended for oncologists, pharmacists, nurses, and other clinicians caring for patients with cancer. Educational Objectives Upon completion of this educational activity participants will be able to:
Disclaimer ©2006 ArcMesa Educators / CMEdiscovery.com. All rights reserved. None of the contents may be reproduced in any form without prior written permission from ArcMesa Educators. The views and opinions expressed in this activity are those of the faculty. They do not reflect the views of Genentech, Inc., OSI Pharmaceuticals, any other manufacturer of pharmaceuticals, or ArcMesa Educators. The recommendations made in this program are based upon a combination of randomized clinical trials, current guidelines, and the clinical practice experience of the participating panelists. Any medications, diagnostic procedures or treatments discussed by the panelists should not be utilized without evaluation of their patient's conditions. Participants are urged to consult the full prescribing information on any drug mentioned in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication.
|
Faculty
|
||||
